Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa
  • Amsterdam
  • Berlin
  • Brussels
  • Copenhagen
  • Danske Bank
  • Denmark
  • DFDS
  • DSV
  • Faroe Islands
  • Greenland
  • Helsinki
  • LEGO
  • Mærsk
  • Novo Nordisk
  • Ørsted
  • Oslo
  • Riga
  • Stockholm
  • Tallinn
  • Vestas Wind Systems
  • Vilnius
  • Warsaw
Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa

Browsing Tag

EASL

3 posts
NNovo Nordisk
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Read More

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

  • 2026-05-24
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…
NNovo Nordisk
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Read More

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

  • 2026-05-21
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…
NNovo Nordisk
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Read More

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

  • 2026-05-19
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…
Denmark
www.europesays.com